scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1090679794 |
P356 | DOI | 10.1186/S12887-017-0923-8 |
P932 | PMC publication ID | 5513165 |
P698 | PubMed publication ID | 28709412 |
P50 | author | Giacomo Cavallaro | Q40566332 |
Luca Filippi | Q55126931 | ||
Giancarlo la Marca | Q56479664 | ||
Simone Donati | Q61216937 | ||
Salvatore Aversa | Q82807268 | ||
P2093 | author name string | Gianpaolo Donzelli | |
Eduardo Villamor | |||
Elettra Berti | |||
Giuseppe Buonocore | |||
Ivan Cortinovis | |||
Silvano Milani | |||
Fabio Mosca | |||
Paola Bagnoli | |||
Gaetano Chirico | |||
Alessandra Pugi | |||
Giulia Forni | |||
Chiara De Angelis | |||
Massimo Dal Monte | |||
Letizia Padrini | |||
Roberta Pasqualetti | |||
Massimo Agosti | |||
Giulia Borsari | |||
Barbara Tomasini | |||
Valentina Bozzetti | |||
Silvia Osnaghi | |||
Paolo Tagliabue | |||
Anna Maria Calvani | |||
Giuseppe Nascimbeni | |||
Angela Bossi | |||
Pina Fortunato | |||
Gabriella Araimo | |||
Giulia Regiroli | |||
Barbara Cavallotti | |||
Maurizio Vanni | |||
P2860 | cites work | Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 | Q24316075 |
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q28111913 | ||
Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. | Q30992212 | ||
Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial | Q31031681 | ||
Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial | Q31151291 | ||
Incidence of retinopathy of prematurity in the United States: 1997 through 2005. | Q33471037 | ||
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action | Q33574011 | ||
Current incidence of retinopathy of prematurity, 1989-1997. | Q33724033 | ||
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins | Q33775844 | ||
Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells | Q34503191 | ||
A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 | ||
Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells. | Q34734440 | ||
Animal models of oxygen-induced retinopathy | Q35109399 | ||
Retinal neovascular markers in retinopathy of prematurity: aetiological implications | Q35590686 | ||
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. | Q35897076 | ||
Oral propranolol in early stages of retinopathy of prematurity | Q35914596 | ||
Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9 | Q35942857 | ||
Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy | Q36035023 | ||
The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index | Q36040633 | ||
Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial). | Q36249663 | ||
Changes in Course of Retinopathy of Prematurity from 1986 to 2013: Comparison of Three Studies in the United States | Q37038705 | ||
Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control | Q37072107 | ||
Induction of apoptosis in infantile hemangioma endothelial cells by propranolol | Q37207112 | ||
Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. | Q37416041 | ||
Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell | Q37452138 | ||
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy | Q37607034 | ||
Retinopathy of prematurity and the oxygen conundrum: lessons learned from recent randomized trials | Q38110392 | ||
Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner | Q38887434 | ||
Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway | Q38904889 | ||
Regulation of glucose transporter protein-1 and vascular endothelial growth factor by hypoxia inducible factor 1α under hypoxic conditions in Hep-2 human cells | Q39280277 | ||
Beta-adrenergic receptor regulation of pigment epithelial-derived factor expression in rat retina | Q40413462 | ||
Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression | Q42434242 | ||
Oxygen-induced retinopathy: a model for vascular pathology in the retina. | Q43221726 | ||
Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy | Q43449364 | ||
A rapid liquid chromatography tandem mass spectrometry-based method for measuring propranolol on dried blood spots | Q43486702 | ||
A randomized controlled trial of propranolol for infantile hemangiomas | Q44267196 | ||
Beta-adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cells | Q44635814 | ||
Propranolol concentrations after oral administration in term and preterm neonates. | Q44663019 | ||
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells | Q44733494 | ||
Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g. | Q45283096 | ||
Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. | Q45418272 | ||
Stabilization of the retinal vascular network by reciprocal feedback between blood vessels and astrocytes. | Q46404558 | ||
Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture | Q46425533 | ||
Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization | Q46459264 | ||
Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system | Q46766115 | ||
Role of beta-adrenergic receptors in inflammatory marker expression in Müller cells | Q46930340 | ||
Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity | Q47629197 | ||
Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization. | Q47880195 | ||
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives | Q47968906 | ||
Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. | Q50442563 | ||
Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. | Q51425178 | ||
Infantile hemangiomas and retinopathy of prematurity: possible association. | Q51818134 | ||
Antiangiogenic effects of β2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. | Q51851194 | ||
Role of host β1- and β2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β3-adrenergic receptors. | Q53574698 | ||
Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. | Q54524067 | ||
Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study | Q56989404 | ||
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age | Q56996636 | ||
Prenatal Risk Factors for Severe Retinopathy of Prematurity Among Very Preterm Infants of the Australian and New Zealand Neonatal Network | Q57391156 | ||
Impact of Placental Restriction on the Development of the Sympathoadrenal System | Q59709862 | ||
Pharmacokinetics and local safety profile of propranolol eye drops in rabbits | Q61700384 | ||
Oxygen-induced retinopathy in the mouse | Q71608431 | ||
Causes of blindness and severe visual impairment in children in Chile | Q72361775 | ||
Age-related changes in sympathetic neurotransmission in rat retina and choroid | Q79316686 | ||
Retinopathy of prematurity | Q79858093 | ||
The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study | Q81920787 | ||
Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? | Q85318492 | ||
Screening examination of premature infants for retinopathy of prematurity | Q85818525 | ||
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice | Q86489017 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | retinopathy of prematurity | Q1423087 |
multicenter clinical trial | Q6934595 | ||
phase II clinical trial | Q42824440 | ||
study protocol | Q111908491 | ||
P304 | page(s) | 165 | |
P577 | publication date | 2017-07-14 | |
P1433 | published in | BMC Pediatrics | Q15750892 |
P1476 | title | Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial | |
P478 | volume | 17 |
Q56527442 | Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial |
Q64249029 | Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study |
Q47708800 | The Beta Adrenergic Receptor Blocker Propranolol Counteracts Retinal Dysfunction in a Mouse Model of Oxygen Induced Retinopathy: Restoring the Balance between Apoptosis and Autophagy. |
Search more.